JP2010213892A - Fibroblast originating from mucosal tissue, tissue improvement material containing the same, manufacturing method of them, and using method of them - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a highly active fibroblast originating from a mucosal tissue, a tissue improvement material containing the same, the manufacturing method of them, and the using method of them. <P>SOLUTION: The method includes a process (14) which cultures the fibroblast originating from the mucosal tissue sampled from a section dyed more deeply with iodine solution than the other section of the mucosal membrane dyed with iodine solution. The method moreover includes a process (15) which produces the tissue improvement material containing the cultured fibroblast. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a fibroblast derived from mucosal tissue, a tissue improving material containing the same, a method for producing the same, and a method for using the same.

  Development of medical technology (so-called regenerative medical technology) that improves the state of living tissue by transplanting living cells into living tissue that has failed due to causes such as injury, aging, or innate factors ing.

  For example, WO 2007/001016 discloses a skin tissue improving material containing fibroblasts derived from oral tissues of humans or other mammals, and a pharmaceutically acceptable medium.

International Publication No. 2007/001016

  However, in the past, fibroblasts collected from mucosal tissues sometimes did not have sufficient activity. That is, the inventor of the present invention has developed a technique for improving biological tissue such as skin tissue by self-transplantation of fibroblasts derived from oral mucosal tissue of a human patient. We experienced a case in which fibroblasts collected from tissues did not have sufficient activity for use in transplantation.

  Specifically, for example, when fibroblasts are collected from the oral mucosal tissues of some patients (for example, elderly patients), the fibroblasts cannot be grown to the number necessary for transplantation by culture. Alternatively, even if the fibroblasts are autotransplanted, a sufficient tissue improvement effect may not be obtained.

  When such a problem occurs, the patient has suffered physical and mental pain, such as having to recollect oral mucosal tissue or give up fibroblast autotransplantation. .

  Thus, the inventor has conducted independent studies, and as a result, has found that fibroblasts with high activity can be reliably collected from a portion of mucosal tissue that is deeply stained with an iodine solution.

  The present invention has been made on the basis of such inventor's unique knowledge. A highly active fibroblast derived from a mucosal tissue, a tissue improving material containing the same, and a method for producing and using the same One of its purposes is to provide it.

  A method according to an embodiment of the present invention for solving the above problems includes a step of staining a mucosal tissue with an iodine solution, and a step of identifying a portion of the stained mucosal tissue that is stained darker than the other portion. And a step of collecting a mucosal tissue piece from the determined portion of the mucosal tissue, and a step of culturing fibroblasts derived from the collected mucosal tissue piece. According to the present invention, highly active fibroblasts derived from mucosal tissue can be provided.

  A method according to an embodiment of the present invention for solving the above-described problem is that a fibroblast derived from a mucosal tissue fragment collected from a portion stained deeper than the other portion of the mucosal tissue stained with an iodine solution. Including the step of cultivating According to the present invention, highly active fibroblasts derived from mucosal tissue can be provided.

  The method may further include a step of producing a tissue improving material containing the cultured fibroblasts. In this way, a tissue improving material containing highly active fibroblasts derived from mucosal tissue can be provided. In this case, the method may further include a step of transplanting the tissue improving material into a living tissue. In this way, a medical technique for transplanting a tissue improving material containing highly active fibroblasts derived from mucosal tissue can be provided. In the above method, the mucosal tissue may be an oral mucosal tissue. In this way, particularly highly active fibroblasts can be used.

  The fibroblast according to one embodiment of the present invention for solving the above-mentioned problem is derived from a mucosal tissue piece collected from a portion stained deeper than the other portion of the mucosal tissue stained with an iodine solution. It is characterized by. According to the present invention, highly active fibroblasts derived from mucosal tissue can be provided. The mucosal tissue may be an oral mucosal tissue. In this way, a particularly active fibroblast can be provided.

  A tissue improving material according to an embodiment of the present invention for solving the above-described problem is a fiber derived from a mucosal tissue piece collected from a portion stained deeper than other portions of a mucosal tissue stained with an iodine solution. It is characterized by containing blast cells. According to the present invention, a tissue improving material containing highly active fibroblasts derived from mucosal tissue can be provided. The mucosal tissue may be an oral mucosal tissue. By doing so, a tissue improving material containing particularly highly active fibroblasts can be provided.

  ADVANTAGE OF THE INVENTION According to this invention, the highly active fibroblast derived from a mucosa tissue, the tissue improving material containing this, a manufacturing method, and the utilization method of these can be provided.

It is explanatory drawing which shows the main processes which may be included in an example of the method which concerns on one Embodiment of this invention. It is explanatory drawing which shows an example of the photograph of the human oral mucosa tissue dye | stained with the iodine solution. It is explanatory drawing which shows an example of the result of having evaluated the yield of the fibroblast from the deeply dyed part and lightly dyed part of an oral mucosa tissue. It is explanatory drawing which shows an example of the result of having evaluated the proliferation ability of the fibroblast obtained from the deeply dyed part and the lightly dyed part of the oral mucosa tissue. It is explanatory drawing which shows an example of the result of having evaluated the collagen production ability of the fibroblast obtained from the deeply dyed part and the lightly dyed part of the oral mucosa tissue. It is explanatory drawing which shows an example of the result of having evaluated the VEGF secretion ability of the fibroblast obtained from the deeply dyed part and the lightly dyed part of the oral mucosa tissue. It is explanatory drawing which shows an example of the result of having evaluated the KGF secretion ability of the fibroblast obtained from the deeply dyed part and the lightly dyed part of the oral mucosa tissue. It is explanatory drawing which shows an example of the result of having evaluated the EGF secretion ability of the fibroblast obtained from the deeply dyed part and the lightly dyed part of the oral mucosa tissue. It is explanatory drawing which shows the concept of the regenerative medicine technique which inject | pours into the said human patient the growth factor secreted by the cell derived from a human patient.

  Hereinafter, an embodiment of the present invention will be described. Note that the present invention is not limited to this embodiment.

  First, an outline of the present invention will be described. FIG. 1 is an explanatory diagram illustrating main steps that can be included in an example of a method according to the present embodiment (hereinafter referred to as “the present method”). That is, this method can be a method including all or part of the steps 11 to 16 shown in FIG.

  For example, in this method, the step 11 of staining the mucosal tissue with an iodine solution and a portion of the stained mucosal tissue that is stained darker than other portions (hereinafter sometimes referred to as “darkly stained portion”). A step 12 of identifying, a step 13 of collecting a mucosal tissue piece from the identified deeply stained portion of the mucosal tissue, and a step 14 of culturing fibroblasts derived from the collected mucosal tissue piece. It can be set as the method of including.

  In this case, one of the characteristic features of this method is that a portion containing highly active fibroblasts in the mucosal tissue is specified in advance before the mucosal tissue piece is collected from the mucosal tissue. That is, as described above, the inventor of the present invention obtains a unique finding that highly active fibroblasts can be efficiently collected from a portion of mucosal tissue that is deeply stained with an iodine solution, thereby completing the present invention. It came to.

  Therefore, in this method, prior to the collection of the mucosal tissue piece as a fibroblast source, the mucosal tissue is stained with an iodine solution (step 11), and then, from other parts of the stained mucosal tissue. A darkly dyed portion is identified (step 12). Then, from the stained mucosal tissue, a mucosal tissue piece is selectively collected from a deeply-stained portion specified in advance (step 13), and fibroblasts derived from the mucosal tissue piece are cultured (step 14).

  The fibroblasts cultured in this manner are particularly highly active fibroblasts among the fibroblasts contained in the stained mucosal tissue. Therefore, this method reliably provides fibroblasts derived from highly active mucosal tissue that can be used for transplantation and other applications.

  In addition, for example, when a mucosal tissue piece collected from the deeply stained part has already been obtained (for example, when the practitioner of the present invention has received provision of the mucosal tissue piece), the method includes steps 11 to 11. Step 14 can be included without including step 13.

  That is, in this case, the method includes a step 14 of culturing fibroblasts derived from a mucosal tissue piece collected from a portion stained deeper than other portions of the mucosal tissue stained with an iodine solution. can do. Such a method also provides fibroblasts derived from highly active mucosal tissue that can be used for transplantation and other uses, as in the above-described method including steps 11 to 14.

  In addition, for example, the method may further include a step 15 of producing a tissue improving material containing the fibroblasts cultured in the step 14. In this case, this method can be a method including steps 11 to 15 or a method including steps 14 and 15 without including steps 11 to 13.

  Thus, this method including the step 15 contains the highly active fibroblasts obtained as described above, and improves the state of the living tissue effectively by being transplanted to the living tissue. Make sure to provide the materials.

  In addition, for example, the method may further include a step 16 of transplanting the tissue improving material produced in the step 15 into a living tissue. In this case, this method can be a method including step 11 to step 16 or a method including step 14 to step 16 without including step 11 to step 13.

  Such a method provides a medical technique for reliably improving the state of the living tissue by implanting the tissue improving material manufactured as described above into the living tissue.

  Next, details of the present invention will be described. In step 11 included in the present method, among the mucosal tissues from which the mucosal tissue pieces can be collected, the mucosal tissue is stained with an iodine solution in order to determine in advance the portion from which the mucosal tissue pieces are collected.

  The iodine solution used here is not particularly limited as long as it is a solution containing iodine as an active ingredient for dyeing. That is, when this iodine solution is brought into contact with the mucosal tissue, the coloration reaction (similar to the iodine starch reaction) of iodine contained in the iodine solution and glycogen granules contained in the mucosal tissue, The iodine is contained in such a manner that the mucosal tissue can be stained.

  The concentration of iodine contained in the iodine solution is not particularly limited as long as the iodine solution can stain the mucosal tissue with a concentration corresponding to the amount of glycogen granules contained in the mucosal tissue. Specifically, the iodine concentration can be, for example, in the range of 1.2 to 6.0 g / 100 mL, and preferably in the range of 1.2 to 3.0 g / 100 mL.

  Therefore, as the iodine solution, for example, compound iodine / glycerin (Lugol solution) which is an aqueous solution containing iodine, potassium iodide and glycerin can be preferably used. The Lugol's solution is a staining solution that contains iodine in a concentration within the above-mentioned range and is used for diagnosis of oral cancer and upper gastrointestinal cancer such as esophageal cancer.

  The mucosal tissue to be stained in step 11 is not particularly limited as long as it can collect a piece of mucosal tissue as a fibroblast source and can be stained with an iodine solution. That is, any mucosal tissue can be used as long as it has a mucosal epithelial layer capable of accumulating glycogen granules and a connective tissue layer containing fibroblasts.

  The mucosal epithelial layer constitutes a surface layer portion of the mucosal tissue, and includes monolayer or multi-layered flat mucosal epithelial cells. The connective tissue layer is covered with a mucosal epithelial layer and includes fibroblasts and an extracellular matrix (collagen or the like) that fills the space between the fibroblasts.

  In the mucosal tissue, glycogen granules produced by the mucosal epithelial cells are accumulated mainly in the mucosal epithelial layer. Therefore, in the mucosal tissue, the mucosal epithelial layer is mainly stained with the iodine solution.

  Specifically, examples of such mucosal tissues include oral mucosal tissues. Oral mucosal tissue is particularly preferred because it has advantages such as relatively easy collection of mucosal tissue fragments and the ability to obtain highly active fibroblasts. The oral mucosal tissue is not particularly limited as long as it is a mucosal tissue constituting a surface layer portion in the oral cavity, and includes a periodontal tissue such as a gingival tissue and a buccal mucosa tissue.

  In addition, the mucosal tissue can be a mucosal tissue of a living body, or can be a mucosal tissue separated from a living body (for example, a mucosal tissue contained in an organ removed by surgery). Among these, a biological mucosal tissue is particularly preferable because it has advantages such as efficient collection of highly active fibroblasts.

  When the purpose is to obtain fibroblasts for transplantation, it is preferable to use a mucosal tissue from which fibroblasts excellent in immunocompatibility with the living body to be transplanted can be obtained. In this respect, the own mucosal tissue to which the fibroblasts are transplanted is particularly preferable because it has an advantage that immune rejection after transplantation can be surely avoided. Specifically, for example, when obtaining fibroblasts to be transplanted into a human patient, it is preferable to use the mucosal tissue of the human patient itself.

  The method for staining the mucosal tissue with an iodine solution is not particularly limited as long as the mucosal tissue can be brought into contact with the iodine solution. That is, for example, in the case of staining oral mucosal tissue, staining is performed by a method in which an iodine solution is included in the oral cavity and held for a predetermined time, or by applying an iodine solution to the oral mucosal tissue using a gauze or a cotton swab. Can be implemented.

  In the mucosal tissue in contact with the iodine solution, all or a part of the mucosal epithelial layer is stained with a color peculiar to the color reaction between iodine and glycogen granules. That is, for example, the oral mucosa tissue is stained brown with the iodine solution.

  In general, the amount of glycogen granules contained in a predetermined range of mucosal tissue is not uniform within the predetermined range. That is, the amount of accumulated glycogen granules differs between a part of the mucosal tissue and the other part.

  For this reason, in the mucosal tissue stained with the iodine solution, a portion having a high content of glycogen granules is stained darker than a portion having a low content of glycogen. Specifically, for example, among the oral mucosa tissues in a predetermined range, when the first range contains more glycogen granules than the second range, the first range is dark brown with the iodine solution. The second range is dyed light brown.

  Thus, in step 11, the entire surface of the mucosal tissue from which the mucosal tissue piece can be collected is stained with a density corresponding to the content of glycogen.

  In step 12, the part of the mucosal tissue stained in step 11 from which a mucosal tissue piece is collected is determined. That is, first, the entire range of the mucosal tissue treated with the iodine solution is observed, and a portion of the mucosal tissue exhibiting a color specific to staining (for example, brownish brown) (hereinafter referred to as “colored portion”). , To distinguish from the part that does not exhibit the color.

  Next, the color density distribution in the colored portion is observed, and a portion in which the color is relatively darker than other portions is specified in the colored portion. Specifically, for example, among the oral mucosal tissues stained in an uneven brown color with an iodine solution, a deeply dyed portion that is relatively darkened in brown color compared with the surroundings is specified.

  Here, FIG. 2 shows an example of a photograph of the oral mucosa tissue of a human patient stained with Lugol's solution. FIG. 2 shows the inside of the oral cavity after the dyeing process. That is, FIG. 2 shows the oral mucosal tissue 20 together with the teeth T and the tongue N between the upper lip L1 and the lower lip L2.

  In FIG. 2, the first portion 21 and the second portion 22 surrounded by a broken line in the oral mucosal tissue 20 are specified as a deeply dyed portion that is darker brown than these peripheral portions 23. Yes. That is, identification of these deeply dyed portions 21 and 22 can be easily performed by visual observation. In the example shown in FIG. 2, the deeply stained portions 21 and 22 are portions other than the gingival tissue 24 in the oral mucosa tissue 20.

  Thus, in step 12, the deeply stained portion of the oral mucosal tissue is determined as the portion where the mucosal tissue piece is actually collected in step 13.

  The part specified as the part from which the mucosal tissue piece is collected is not limited to the part stained in the darkest color in the mucosal tissue. That is, for example, the colored part can be divided into three or more parts having different color densities, and it is not preferable to collect the mucosal tissue piece from the darkest part (for example, the mucosal tissue piece If there is a situation in which the collection causes excessive pain to the human patient), it can be determined to be another portion that is darker than the lightest portion. In addition, when the range of the darkest part is smaller than the size of the mucosal tissue piece to be collected, in addition to the darkest part, the next darkest part may be a part from which the mucosal tissue piece is collected. it can.

  Further, the color strength is relatively determined within a predetermined range of the mucosal tissue subjected to evaluation. That is, since there is an individual difference in the color density, it is not easy to determine the color density on an absolute basis. On the other hand, if the portion is stained with a relatively dark color in the mucosal tissue of each living body (for example, each human patient), fibroblasts with relatively high activity can be reliably obtained.

  Of course, if a criterion that can be applied in common between a plurality of living bodies can be established when extracting a deeply dyed portion from a colored portion, the color density can also be determined based on the criterion. The method for determining the color density of the mucosal tissue is not particularly limited. For example, as described above, the observer can easily determine visually.

  Thus, in step 12, a predetermined range of the deeply stained portion is selected as a portion from which a piece of mucosal tissue is collected out of a relatively wide range of mucosal tissue.

  In step 13, a piece of mucosal tissue that is a fibroblast source is selectively collected from the deeply stained part specified in step 12. That is, for example, out of a wide range of mucosal tissues, a piece of mucosal tissue is collected only from the deeply stained area where highly active fibroblasts are reliably obtained. The excised mucosal tissue piece includes the mucosal epithelial layer and the connective tissue layer as described above.

  The size of the mucous membrane tissue piece is appropriately determined according to transplantation and other uses. That is, for example, when fibroblasts are used for transplantation, considering that the fibroblasts are amplified in a culture system, a mucosal tissue of a size that allows the number of fibroblasts necessary for the transplantation to be obtained. Collect a piece. Specifically, when an oral mucosa tissue piece is collected from a human patient for autotransplantation into the skin tissue, for example, an oral mucosa tissue piece of about 3 to 5 mm square and a thickness of about 3 mm is collected.

  The method for collecting the mucosal tissue piece is not particularly limited. That is, for example, by using a surgical scalpel, scissors or the like to cut out a predetermined range of the deeply stained portion by a predetermined depth, a mucosal tissue piece of a predetermined size can be easily separated from a living body. In addition, since the collected mucosal tissue fragments are derived from the deeply stained part, the mucosal epithelial layer has a color peculiar to staining with an iodine solution.

  Thus, in step 13, a mucosal tissue piece containing relatively highly active fibroblasts is reliably collected from the mucosal tissue.

  In step 14, fibroblasts derived from the mucosal tissue pieces collected in step 13 are cultured. That is, first, a mucosal tissue piece separated from a living body as described above is prepared, and then fibroblasts derived from the mucosal tissue piece are cultured in vitro.

  Here, the fibroblasts derived from the mucosal tissue fragments were generated by the proliferation of the fibroblasts (primary fibroblasts) contained in the collected mucosal tissue fragments and the primary fibroblasts. And both fibroblasts.

  The method for culturing fibroblasts is not particularly limited as long as it can selectively cultivate fibroblasts derived from mucosal tissue fragments and does not excessively impair the activity of the fibroblasts. The method can be applied.

  That is, for example, a mucosal tissue piece is placed on a culture substrate having a surface suitable for fibroblast adhesion, and the mucosal tissue piece is placed in a predetermined culture solution at a predetermined temperature (eg, 37 ° C.), Culturing is performed under a predetermined atmosphere (for example, 5% carbon dioxide / 95% air). In this case, some of the fibroblasts contained in the mucosal tissue piece grow while adhering to the culture substrate and spread on the culture substrate. The mucosal tissue piece can also be used after the mucosal epithelial layer is preliminarily removed by an instrument such as a scalpel or scissors or an enzyme treatment and is mainly composed of a connective tissue layer.

  The culture substrate is not particularly limited as long as fibroblasts can adhere and can proliferate without excessively degrading its activity. For example, resin culture dishes, culture flasks, and porous substrates. A known substrate such as a gel substrate can be used.

  The culture solution is not particularly limited as long as fibroblasts can proliferate without excessively impairing its activity. For example, basal media such as α-MEM medium and DMEM medium, other serum and antibiotics, etc. A well-known culture solution, such as a culture solution prepared by adding components, can be used.

  In the case of culturing fibroblasts in a culture solution to which serum is added while aiming to be used for transplantation, from the viewpoint of immunocompatibility, the serum is the serum of the living organism to be transplanted or It is preferable to use the same kind of serum as the living body.

  That is, for example, when fibroblasts derived from the oral mucosal tissue of a human patient are cultivated in a culture solution to which serum has been added for autologous transplantation to the human patient, It is preferred to use the patient's own serum. Of course, a culture solution (serum-free culture solution) to which no serum is added can also be used.

  The culture system thus established can be, for example, a culture system substantially free of cells other than mucosal tissue-derived fibroblasts (the fibroblasts are dominant).

  In addition, one of the purposes of culturing in step 14 is to amplify the number of fibroblasts derived from mucosal tissue while maintaining its activity. Accordingly, the culture of fibroblasts continues until the number reaches or exceeds the predetermined number required for transplantation or other uses.

  Further, when fibroblasts grow on the culture substrate and reach confluence (dense state), the fibroblasts can be passaged. The number of passages is not particularly limited as long as the activity of the fibroblasts is not excessively impaired, and can be, for example, 10 or less, preferably within the range of 3 to 6 passages.

  In addition, some or all of the cultured fibroblasts can be cryopreserved. The cryopreservation method is not particularly limited as long as it does not excessively impair the viability and activity of the fibroblasts after thawing. For example, it may be a known method used for cryopreservation of fibroblasts. it can.

  Moreover, in the process 14, the activity of the cultured fibroblast can also be confirmed. That is, for example, by measuring the change in the number of fibroblasts during a predetermined culture period, the proliferative ability of the fibroblasts can be evaluated.

  In addition, for example, an extracellular matrix such as collagen produced by fibroblasts during a predetermined culture period, or a growth factor such as VEGF (vascular endothelial growth factor), KGF (keratinocyte growth factor), EGF (epidermal growth factor), etc. These production functions inherently possessed by the fibroblast can be evaluated by measuring the amount of.

  Here, the activity of fibroblasts derived from mucosal tissue is higher than that of fibroblasts derived from skin tissue. That is, for example, in the above-mentioned International Publication No. 2007/001016, the proliferation ability of fibroblasts derived from gingival tissue (a part of oral mucosal tissue) and the secretion ability of growth factors (for example, VEGF, KGF), It has been shown to be significantly higher than fibroblasts derived from skin tissue. In addition, all the content which this international publication 2007/001016 discloses is integrated in this specification as a reference.

  Furthermore, the fibroblasts derived from the deeply stained part of the mucosal tissue are more proliferative, extracellular matrix (collagen etc.) and growth factors (VEGF, KGF) than the fibroblasts derived from the thinner stained part. , EGF, etc.) and other activities are remarkably high.

  Thus, in step 14, fibroblasts that maintain their original activity at a high level are cultured and expanded. Therefore, according to this method including such a step 14, as described above, highly active fibroblasts that can be used for transplantation and other uses can be produced efficiently and reliably.

  That is, for example, when producing fibroblasts to be used for autotransplantation of human patients, a large amount of highly active fibroblasts derived from the dark-stained portion of the oral mucosa tissue of the human patients themselves in a short period of time. Can be manufactured. In particular, only a small amount of a mucous membrane tissue piece is collected once from a pre-specified deeply stained part even from a patient who has not been able to collect highly active fibroblasts conventionally (for example, an elderly patient). Thus, highly active self-fibroblasts can be reliably obtained.

  In addition, the highly active fibroblasts thus produced can be used not only for transplantation but also for various purposes such as in vitro screening tests.

  In step 15, a tissue improving material containing fibroblasts obtained by the culture in step 14 is produced. That is, first, a predetermined number of highly active fibroblasts derived from mucosal tissue are prepared. Specifically, for example, fibroblasts cultured on the culture substrate in step 14 are collected. Also, for example, the fibroblasts that have been cryopreserved after culturing in step 14 are thawed.

  Then, a tissue improving material is prepared as a composition containing the fibroblasts thus prepared and having excellent biocompatibility. That is, for example, a tissue improving material containing fibroblasts and a pharmaceutically acceptable medium is prepared.

  The medium is not particularly limited as long as it can maintain its survival when in contact with fibroblasts and has biocompatibility that can be used for transplantation. That is, as the medium, for example, an aqueous solution such as a buffer solution or a culture solution whose osmotic pressure is appropriately adjusted can be preferably used. In these cases, the tissue improving material is a liquid composition (suspension) in which fibroblasts are dispersed in a medium.

  The tissue improving material can also contain subcomponents other than fibroblasts and media. Examples of subcomponents include antibiotics, nutritional components (for example, various vitamins, amino acids, glucose), enzymes, coenzymes, preservatives, growth factors (for example, VEGF, KGF, EGF), cytokines, various drugs ( Examples thereof include anti-inflammatory agents) and pigments. However, it is preferable that the tissue improving material does not substantially contain an immunogenic component (eg, a heterologous protein).

The number of fibroblasts contained in the tissue improving material is appropriately determined according to conditions such as the state of the living tissue to be transplanted. That is, when the tissue improving material is a liquid composition containing fibroblasts derived from oral mucosa tissue of a human patient, the tissue improving material is, for example, 1 × 10 ⁶ to 1 × 10 ⁸ per mL. (Preferably 1 × 10 ⁷ to 1 × 10 ⁸ cells) of the fibroblasts.

  The tissue improving material can also contain a growth factor secreted by fibroblasts. That is, when the tissue improving material contains fibroblasts derived from the oral mucosal tissue of a human patient, the tissue improving material can contain, for example, VEGF, KGF, and EGF.

  Furthermore, in this case, the concentration of VEGF is, for example, 30 (pg / mg-protein) or more, preferably 40 (pg / mg-protein) or more, more preferably 50 (pg / mg-protein) or more. It is. More specifically, the VEGF concentration is, for example, in the range of 30 to 100 (pg / mg-protein), preferably in the range of 40 to 100 (pg / mg-protein), more preferably 50 to It is within the range of 100 (pg / mg-protein).

  Moreover, the density | concentration of KGF is 500 (pg / mg-protein) or more, for example, Preferably it is 1000 (pg / mg-protein) or more, More preferably, it is 1500 (pg / mg-protein) or more. More specifically, the KGF concentration is, for example, in the range of 500-2500 (pg / mg-protein), preferably in the range of 1000-2500 (pg / mg-protein), more preferably 1500-500. It is in the range of 2500 (pg / mg-protein).

  Moreover, the density | concentration of EGF is 500 (pg / mg-protein) or more, for example, Preferably it is 1000 (pg / mg-protein) or more, More preferably, it is 1500 (pg / mg-protein) or more. More specifically, the EGF concentration is, for example, in the range of 500 to 2000 (pg / mg-protein), preferably in the range of 1000 to 2000 (pg / mg-protein), more preferably 1500 to 2000. It is within the range of 2000 (pg / mg-protein).

  The tissue improving material can contain one or more of VEGF, KGF, and EGF at the aforementioned concentrations, and preferably contains all of VEGF, KGF, and EGF at the aforementioned concentrations.

  Thus, in step 15, a tissue improving material that is a composition for transplantation that contains highly active fibroblasts derived from mucosal tissue and is used to improve the state of living tissue is prepared. Therefore, according to this method including such a step 15, as described above, a tissue improving material that effectively improves the state of the living tissue by being transplanted into the living tissue can be reliably manufactured.

  That is, for example, when producing a tissue improving material for autotransplantation into a human patient, the transplanted living body contains highly active fibroblasts derived from the deeply stained part of the oral mucosa tissue of the human patient. A tissue improving material that effectively improves the state of the tissue can be produced in a short period of time.

  In particular, it is possible to reliably manufacture a tissue improving material that provides a sufficient tissue improving effect even for patients (for example, elderly patients) who have not been able to obtain a tissue improving effect by transplantation.

  In step 16, the tissue improving material produced in step 15 is transplanted into a living tissue. The living tissue to be transplanted is a tissue in which a problem has occurred due to a cause such as injury or illness, aging, or an innate factor, and is not particularly limited as long as the tissue should be improved.

  That is, for example, if the tissue originally contains fibroblasts or cells having the same function as fibroblasts (for example, cells that secrete extracellular matrix and growth factors similar to fibroblasts) The state can be improved by transplanting the tissue improving material according to the present invention.

  Specifically, examples of such tissues include skin tissues, oral tissues, esophageal tissues, and vaginal mucosa tissues.

  That is, for example, a part of the skin tissue of a human patient that has a defect in appearance or function (for example, wrinkles, pregnancy lines, acne scars, depressed scars, scars, atraumatic skin depression, acne vulgaris, etc. Portions and portions with reduced water retention (moisture) and elasticity) can be targeted for transplantation.

  The tissue to be transplanted can be a tissue other than the mucosal tissue from which the fibroblasts contained in the tissue improving material are collected. That is, for example, when a tissue improving material containing fibroblasts derived from the oral mucosal tissue of a human patient is prepared, the state of the skin tissue can be improved by transplanting the tissue improving material into the skin tissue. it can.

  Of course, the tissue improving material can also be transplanted into the mucosal tissue from which the fibroblasts are collected. That is, for example, when a tissue improving material containing fibroblasts derived from the oral mucosal tissue of a human patient is produced, the state of the oral mucosal tissue is improved by transplanting the tissue improving material to the oral mucosal tissue. be able to.

  Further, in order to avoid immune rejection associated with transplantation, the living body to which the tissue improving material is transplanted is preferably a living body from which a mucosal tissue piece is collected in order to produce the tissue improving material. That is, for example, a tissue improving material containing fibroblasts derived from the oral mucosal tissue of a human patient is preferably autografted into the human patient's own tissue.

  The transplantation method is not particularly limited as long as the fibroblast contained in the tissue improving material can be transplanted to a living tissue while alive, and a known method can be used. That is, for example, when the tissue improving material is a liquid composition containing fibroblasts, the tissue improving material is injected into the living tissue using an injection device such as a syringe.

  Specifically, for example, when autotransplanting a liquid tissue improving material containing fibroblasts derived from oral mucosa tissue of a human patient into the skin tissue of the human patient itself, the tissue improvement is performed using a syringe. The material is injected near the boundary between the epidermis layer and the dermis layer of the skin tissue or into the dermis layer.

The amount of the tissue improving material to be transplanted is appropriately determined according to conditions such as the state of the living tissue to be transplanted. That is, for example, when a liquid tissue improving material containing fibroblasts derived from oral mucosal tissue of a human patient is self-transplanted into skin tissue, the tissue improving material used for one injection is, for example, 1 × 10 The amount may be about several mL containing ⁶ to 1 × 10 ⁸ (preferably 1 × 10 ⁷ to 1 × 10 ⁸ ) fibroblasts.

  In addition, the number of times (one or more times) the tissue improving material is transplanted, the location (one or more locations), and the spatial and temporal intervals of each transplant when transplanting to multiple times or multiple locations are in various conditions. Determine accordingly.

  Thus, in step 16, a tissue improving material containing fibroblasts maintaining their original activity at a high level is transplanted into a living tissue. Therefore, according to this method including such a step 16, as described above, the state of the living tissue can be reliably improved by transplanting the tissue improving material.

  That is, for example, in the case of autotransplanting a tissue improving material to a human patient, highly active fibroblasts derived from the deeply stained portion of the oral mucosa tissue of the human patient itself, the tissue of the human patient (for example, By transplanting into skin tissue), the state of the tissue can be reliably improved.

  In particular, a sufficient tissue improvement effect can be brought about even for a patient (for example, an elderly patient) who could not always obtain a tissue improvement effect by transplantation.

  It should be noted that the tissue improvement effect can be obtained not only in the local portion where the tissue improving material is transplanted but also in the surrounding area in the living tissue that is the target of transplantation. This is thought to be due to the fact that fibroblasts transplanted into living tissue not only proliferate, but also supply extracellular matrix and growth factors to the surrounding tissue. That is, fibroblast transplantation can improve the proliferation and function of fibroblasts and other cells originally present in living tissue.

  Therefore, for example, a tissue-improving material containing fibroblasts derived from the oral mucosa tissue of the human patient is applied to a depressed affected part (for example, a part where wrinkles are formed) of the skin tissue of the human patient. In the case of autotransplantation, not only the affected area but also the surrounding skin tissue can improve the water retention, elasticity, tension, gloss and the like. Moreover, this organizational improvement effect is maintained for several years.

  As described above, the present invention effectively improves the state of the living tissue by transplanting living fibroblasts derived from mucosal tissue into the living tissue that has failed due to causes such as injury, aging, and innate factors. It can be applied to medical technology that is improved. In particular, according to the autotransplantation treatment method in which a tissue body improving material containing fibroblasts derived from a human patient's own mucosal tissue is produced, and the tissue body improving material is transplanted into the human patient, the transplantation occurs in another family transplantation. The tissue of the human patient can be effectively improved while reliably avoiding problems such as immune rejection and tumor formation caused by ES cells and iPS cells.

  Specifically, the present invention, for example, by self-transplanting fibroblasts derived from the oral mucosal tissue of the patient itself into a part of the skin tissue of a human patient that has a defect in appearance or function. Providing medical technology that improves the appearance and function. Therefore, the present invention is particularly applicable to various medical fields such as general surgery, plastic surgery, and cosmetic surgery.

  Next, specific examples according to the present embodiment will be described. The collection and use of oral mucosal tissue fragments from human patients shown in this example was approved in advance by the Ethics Committee of the Nagoya University School of Medicine, and with the consent of the human patients, oral surgery at Nagoya University Hospital It was implemented in.

[Collecting oral mucosa tissue pieces]
First, the oral mucosa tissue of an adult human patient was stained with Lugol's solution containing iodine at a concentration of 1.2-1.6 g / 100 mL. Next, the entire oral mucosa tissue after staining was visually observed. Here, the oral mucosal tissue of the patient is stained unevenly in the same manner as in FIG. 2 described above, and the relatively darkly stained part can be easily distinguished from the surrounding lightly stained part. It was.

  Therefore, among the stained oral mucosal tissues, a deeply stained portion that is stained particularly dark brown is identified as a portion from which a mucosal tissue piece is collected. Then, an oral mucosal tissue piece having a size of about 3 mm square and a thickness of about 3 mm was collected from the deeply stained portion using a scalpel.

  In addition, as a control, an oral mucosa tissue piece of the same size was also obtained from a portion of the stained oral mucosal tissue other than the deeply stained portion and stained light brown (hereinafter referred to as “lightly stained portion”). Were collected.

[Culture of fibroblasts]
The collected oral mucosa tissue pieces were treated with a collagenase solution (concentration 5 mg / mL, Wako Pure Chemical Industries, Ltd.) at 37 ° C. for 2 hours. The treated oral mucosa tissue pieces were transferred to a culture dish having a diameter of 35 mm and cultured in a DMEM culture solution in an atmosphere of 37 ° C., 5% carbon dioxide / 95% air. Thus, fibroblasts derived from oral mucosal tissue pieces adhered to the bottom surface of the culture dish were obtained.

Next, the fibroblasts were collected and seeded in a culture flask (T75 flask) by about 4 × 10 ⁴ cells. Four culture flasks were used for each of the fibroblasts derived from the deeply stained area and the fibroblasts derived from the lightly stained area.

  As the culture solution, DMEM culture solution (No. 10099-141, Invitrogen Corporation) and 1% antibiotic-antifungal agent (No. 15240-062, Invitrogen Corporation) added (10%). No. D6429, Sigma-Aldrich Co.). The fibroblasts were cultured for 7 days in an atmosphere of 37 ° C., 5% carbon dioxide / 95% air.

[Yield of fibroblasts]
The fibroblast yield was evaluated for each of the deeply dyed area and the lightly dyed area. That is, by treating each culture flask after culturing for 7 days as described above with a commercially available cell dissociating agent (TrypLE Select, Invitrogen Co., Ltd.), the fibroblasts adhering to each culture flask are removed. Released and collected. The number of the recovered fibroblasts was measured using a commercially available cell counting analyzer (CASY (registered trademark), Charlotte System GmbH).

  FIG. 3 shows the measurement results. In FIG. 3, the vertical axis shows the number of cells per piece of collected oral mucosa tissue (about 3 mm square, about 3 mm thick), and the hatched bar graph shows the result of the deeply stained part, The white bar graph shows the result of the lightly stained part. As shown in FIG. 3, statistically significantly more fibroblasts could be obtained from the deeply stained part than in the lightly stained part.

[Proliferation capacity of fibroblasts]
For each of the four culture flasks, the ratio of the number of cells after 7 days of culture to the number of seeded cells was calculated as the growth rate (%).

  FIG. 4 shows the calculation result of the proliferation rate. In FIG. 4, the vertical axis indicates the growth rate (%), the hatched bar graph indicates the result of fibroblasts derived from the darkly stained part (number of tests n = 4), and the open bar graph indicates lightly stained The results of the fibroblasts derived from the part (test number n = 4) are shown. As shown in FIG. 4, the proliferation rate of fibroblasts derived from the deeply stained area was statistically significantly higher than that of fibroblasts derived from the lightly stained area.

[Collaboration ability of fibroblasts]
Each well of a 6-well culture plate containing a DMEM culture solution containing 10% fetal bovine serum and 1% antibiotic-antifungal as described above was seeded with fibroblasts at 37 ° C., 5% carbon dioxide / The culture was performed in an atmosphere of 95% air.

  Thereafter, when the fibroblasts proliferated and became 100% confluent, the culture solution was collected from the wells. The collected culture medium was centrifuged at 4 ° C. and 10,000 rpm for 5 minutes, and the supernatant was collected. The collected supernatant was stored frozen at −70 ° C. as necessary. Then, the amount of collagen contained in each supernatant was measured using a commercially available collagen measurement kit (Sircol, Biocolor Ltd.).

  FIG. 5 shows the measurement results of collagen production ability. In FIG. 5, the vertical axis indicates collagen production capacity (mg / mL), and the hatched bar graph indicates the results of fibroblasts derived from the darkly stained area (test number n = 4), The bar graph shows the results of fibroblasts derived from the lightly stained part (number of tests n = 4). As shown in FIG. 5, the collagen-producing ability of fibroblasts derived from the deeply stained area was statistically significantly higher than that of fibroblasts derived from the lightly stained area.

[Growth factor secretion ability of fibroblasts]
The fibroblasts recovered from the culture flask were seeded in each well of a 6-well culture plate containing the DMEM culture solution containing 10% fetal bovine serum and 1% antibiotic-antimycotic as described above. The culture was performed in an atmosphere of 5% carbon dioxide / 95% air.

  Thereafter, when the fibroblasts proliferated and became 100% confluent, the culture solution was removed by suction from the wells and washed twice with PBS (phosphate buffer solution). Next, the DMEM culture solution to which no serum was added was added to the wells and the culture was continued. Then, 48 hours after replacing the culture medium with serum-free DMEM culture medium, 1 mL of the culture medium was collected from each well.

  The collected culture was centrifuged at 4 ° C. and 10,000 rpm for 5 minutes, and the supernatant was collected. The collected supernatant was stored frozen at −70 ° C. as necessary. And each ELISA method using commercially available VEGF measurement kit (Immunoassay kit VEGF, Biosource), KGF measurement kit (Quantikine (registered trademark), R & D Systems) and EGF measurement kit (Quantikine (registered trademark), R & D Systems), VEGF, KGF and EGF contained in the supernatant were each quantified. The amount (pg) of growth factor contained in the supernatant per total amount (mg) of protein contained in the supernatant was evaluated as the secretory ability of the growth factor of fibroblasts.

  FIG. 6, FIG. 7 and FIG. 8 show the evaluation results for VEGF, KGF and EGF, respectively. 6 to 8, the vertical axis indicates the secretion ability of growth factor (pg / mg-protein), and the hatched bar graph indicates the results of fibroblasts derived from the darkly stained part (number of tests n = 3). The white bar graph shows the results of fibroblasts derived from the lightly stained area (number of tests n = 3).

  As shown in FIG. 6 to FIG. 8, the VEGF secretion ability, the KGF secretion ability and the EGF secretion ability of the fibroblasts derived from the deeply stained part are statistically compared to those of the fibroblasts derived from the lightly stained part. It was significantly higher.

  Specifically, a serum-free culture solution obtained by culturing fibroblasts derived from a deeply stained part for 48 hours is about 60 (pg / mg-protein) VEGF, about 2000 (pg / mg-protein) KGF, about 1600. (Pg / mg-protein) of EGF, respectively.

  Thus, the fibroblasts derived from the deeply dyed part had a high level of growth ability and growth factor secretion ability. On the other hand, it has already been demonstrated that a tissue improving material containing fibroblasts derived from mucosal tissue can be transplanted into a living tissue to obtain an improving effect on the tissue.

  That is, for example, by injecting an aqueous solution containing fibroblasts derived from oral mucosal tissue into the depressed portion of the skin tissue where wrinkles are formed, the transplanted fibroblasts and the existing skin tissue The fibroblasts of the cells can proliferate and push up the depression, reducing the degree of depression or eliminating the depression. In addition, the transplanted fibroblasts move not only to the portion where the tissue improving material is injected, but also to the periphery thereof, and are engrafted. Also in this surrounding skin tissue, physical and physiological conditions such as water retention and elasticity are improved. Moreover, this improvement effect lasts for several years.

  Therefore, it is clear that the tissue can be effectively improved by transplanting a tissue improving material containing highly active fibroblasts derived from the deeply stained part as described above into a living tissue in the same manner as before. .

  Next, an invention related to regenerative medicine technology (hereinafter referred to as “GF invention”) for improving a tissue by injecting a growth factor (GF) derived from a human patient into the tissue of the human patient itself will be described. . FIG. 9 is an explanatory diagram showing the concept of the regenerative medical technique according to the GF invention.

  Currently, the development of regenerative medical techniques for transplanting stem cells having various differentiation potentials such as embryonic stem cells (ES cells), induced pluripotent stem cells (iPS cells), and other stem cells into a living body is in progress. However, with regard to such a technique for transplanting stem cells, the risk that the transplanted stem cells become tumors has been pointed out.

  On the other hand, for example, regenerative medical technology that improves the function of the heart by culturing myocardial cells or myoblasts in vitro and constructing a cell sheet and transplanting the cell sheet into the heart has been developed. And certain effects are recognized. However, it is not clear whether this effect is due to the cells themselves contained in the transplanted cell sheet engrafting and functioning in the heart tissue.

  In this regard, the inventor has focused on the possibility that the function of the heart may be improved despite the subsequent death of the cells contained in the transplanted cell sheet. That is, the inventor thought that the growth factor secreted by the transplanted cells activated the existing cells in the living tissue, thereby improving the structure and function of the tissue.

  The GF invention has been made on the basis of such inventor's unique knowledge, and provides a tissue improving material that is excellent in safety and has a high therapeutic effect, and a method for producing and utilizing the same.

  The tissue improving material according to the GF invention is prepared from a supernatant of a culture solution in which cells derived from a human patient are cultured, and contains a growth factor secreted by the cells into the culture solution as an active ingredient.

  Cells derived from a human patient are not particularly limited as long as they are cells collected from the human patient and cells derived from the cell, and can secrete growth factors into the culture medium when cultured in vitro. I can't. That is, these cells include fibroblasts derived from the above mucosal tissue, fibroblasts derived from other tissues, adipose stem cells derived from adipose tissue, myoblasts, osteoblasts, chondroblasts, neuroblasts Cells, other stem cells (bone marrow stem cells, muscle stem cells, epithelial stem cells, dental pulp stem cells, etc.), iPS cells can be used. As mentioned above, the mucosal tissue-derived fibroblasts include mucosal tissue fragments collected from a portion of the mucosal tissue stained with an iodine solution as described above (particularly the oral mucosal tissue) that is darker than the other part. The derived fibroblasts can be preferably used.

  As stem cells, ES cells, mesenchymal stem cells derived from bone marrow and other tissues (MSC), and other tissue stem cells (somatic stem cells) that maintain differentiation ability as described above and various progenitor cells may be used. it can. As ES cells and iPS cells, those prepared by a known method using cells of human patients themselves can be used.

  The growth factor contained in the tissue improving material is not particularly limited as long as it is secreted by cells derived from a human patient. That is, this tissue improving material is, for example, VEGF, KGF, EGF, fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), nerve growth factor (NGF), tumor growth. One or more selected from the group consisting of factors (TGF) can be contained.

  Specifically, for example, when fibroblasts derived from mucosal tissues such as oral mucosal tissues are used, the tissue improving material is one or more selected from the group consisting of VEGF, KGF, and EGF. Preferably all of these are included.

  Thus, the tissue improving material according to the GF invention contains, as an active ingredient, a growth factor derived from the cells of the human patient who is the subject of treatment. Therefore, according to this tissue improving material, it is possible to provide a regenerative medical technique that reliably avoids immune rejection, has a very low risk of tumor formation, and is excellent in safety.

  The tissue-improving material comprises a preparation step for preparing cells derived from a human patient, a culturing step for culturing the cells, and a proliferation secreted by the cells into the culture solution from the supernatant of the culture solution in which the cells are cultured. And a preparation step of preparing a tissue improving material containing a factor.

  In addition, when the culture solution containing the growth factor secreted by the cell derived from a human patient or the supernatant of the said culture solution can be obtained, said preparation process and culture | cultivation process become unnecessary. Therefore, in this case, the method includes a step of preparing a tissue improving material containing a growth factor secreted into the culture medium from the supernatant of the culture medium in which cells derived from a human patient are cultured. It becomes.

  The preparation step may include a step of collecting cells from a human patient. In this case, the preparation step includes, for example, a step of collecting a tissue piece including a target cell from the tissue of a human patient, as in the above-described step 13.

  The tissue piece to be collected is not particularly limited as long as it contains a target cell. That is, when fibroblasts are used, for example, a mucosal tissue piece (for example, the above-described oral mucosa tissue piece), a fat tissue piece, and a skin tissue piece (particularly a dermis layer portion) are collected. When mesenchymal stem cells are used, for example, bone marrow, umbilical cord, placenta, and other tissue pieces containing mesenchymal stem cells are collected.

  Moreover, when using ES cells or iPS cells, the preparation step may include a step of producing the ES cells or iPS cells. In this case, in the preparation step, ES cells or iPS cells are prepared by a known method using the cells of the human patient themselves. Of course, when ES cells or iPS cells already produced are used, the step of producing them is unnecessary.

  In the culturing step, the cells prepared in the preparation step are cultured in vitro as in the above-described step 14. At this time, when a small number of stem cells and progenitor cells contained in the tissue piece are used, the stem cells and progenitor cells are selectively proliferated. As a method for selecting and culturing these cells, known methods can be used. The culture solution is not particularly limited as long as it allows the growth factor to be secreted by the cells. For example, a serum-free culture solution to which no serum is added is preferable. Moreover, when culturing cells derived from a human patient using a culture solution to which serum has been added, it is preferable to use the human patient's own serum as the serum.

  In the culturing step, cells are cultured in a culture solution for a predetermined time, and then the culture solution is collected. When culturing is continued, a fresh culture solution is again supplied to the cells and further cultured for a predetermined time. The timing and number of times the culture medium is collected in the culturing step are appropriately determined according to conditions such as the amount of growth factor secreted by the cells and the treatment schedule using the cells themselves.

  That is, for example, when the above-mentioned mucosal tissue-derived fibroblasts are autotransplanted, cells derived from a human patient are cultured for transplantation into the human patient, and when the cells are amplified, the culture is performed. Is continued until the number of cells reaches the target value required for transplantation. Therefore, in this case, the culture solution is collected as many times as the number of replacement of the culture solution at the timing of replacement of the culture solution during the culture period in which the cells are amplified. The collected culture solution can be refrigerated or frozen.

  Conventionally, in the culture process for amplifying such cells for autotransplantation, the collected culture medium has been discarded. However, this culture solution is a so-called conditioned medium unique to the human patient to be treated, and is a growth factor cocktail containing abundant growth factors produced by the cells of the human patient itself. Therefore, in the GF invention, the collected culture solution is used as a source of growth factors for human patients themselves. Therefore, a tissue improving material containing abundant growth factors of a human patient can be easily and reliably produced by a method similar to a conventional autograft treatment method.

  In the preparation step, a tissue improving material containing a growth factor contained in the supernatant of the culture medium collected as described above and a pharmaceutically and medically acceptable medium is prepared. As the medium, water or an aqueous solution can be preferably used. The aqueous solution is not particularly limited as long as it can be transplanted into a living body. For example, an aqueous solution whose osmotic pressure and pH are adjusted to be equal to that of a body fluid can be preferably used. Specifically, for example, so-called physiological saline, phosphate buffer (PBS), and serum-free culture solution can be used.

  In this preparation step, for example, a tissue improving material is prepared by subjecting the collected culture supernatant to a treatment such as concentration and purification. The supernatant of the culture solution can be prepared as a supernatant after centrifuging the culture solution to precipitate cells, cell debris and other solid components contained in the culture solution. The growth factor contained in the supernatant can be concentrated, for example, by using an ultrafiltration membrane that does not allow the growth factor contained in the supernatant to pass through. In addition, when the collected culture supernatant contains a growth factor contained in the culture and a pharmaceutically and medically acceptable medium, the supernatant is used as it is. It can also be used as a tissue improving material.

  The concentration of the growth factor contained in the tissue improving material is not particularly limited as long as a certain effect can be expected by injecting the tissue improving material into a human patient, and can be set as appropriate. That is, for example, when using fibroblasts derived from mucosal tissues such as the aforementioned oral mucosal tissues, the tissue improving material is one or more selected from the group consisting of VEGF, KGF, EGF, and the like. It is preferable to contain in the density | concentration range contained in the structure | tissue improvement material containing the said fibroblast.

  In addition, the tissue improving material can contain a plurality of types of growth factors with substantially the same composition as the composition in the culture supernatant used for the production. That is, for example, when using fibroblasts derived from mucosal tissues such as the above-mentioned oral mucosal tissues, the tissue improving material is VEGF, KGF and EGF, and the supernatant of the culture solution in which the fibroblasts are cultured. It can contain in the density | concentration ratio substantially the same as the density | concentration ratio of these growth factors in the inside. In this case, the tissue improving material can contain, for example, a plurality of types of VEGF (a part or all of the so-called VEGF family) secreted by fibroblasts into the culture solution.

  Moreover, since the tissue improving material is produced from the culture supernatant as described above, it does not contain cells. Further, the tissue improving material is preferably a liquid suitable for injection into a living tissue, and particularly preferably an aqueous solution. In addition, it is preferable to implement the above-mentioned cell culture and preparation of a tissue improving material in an appropriate GMP (Good Manufacturing Practice) facility.

  And the method of improving a human patient's tissue using a tissue improving material includes the process of inject | pouring the tissue improving material manufactured as mentioned above into a human patient's tissue. This method can also include all or part of the above-mentioned preparatory steps, culture steps and preparation steps.

  The biological tissue into which the tissue improving material is injected is a tissue that has failed due to causes such as injury and illness, aging, and innate factors, as in the above-described step 16, and is particularly limited if it is a tissue whose state should be improved. I can't. That is, for example, skin tissue, brain tissue, spinal tissue, nerve tissue (tissue surrounding the nerve), bone marrow tissue, bone tissue, cartilage tissue, muscle tissue, heart tissue (myocardial tissue), liver tissue, pancreas tissue, kidney tissue, The tissue can be improved by injecting the tissue improving material into a biological tissue such as a vascular tissue, an oral tissue, an esophageal tissue, or a vaginal mucosa tissue. In addition, injection | pouring of a liquid structure | tissue improvement material can be performed using injection devices, such as a syringe.

  Since the tissue improving material prepared from the culture supernatant in this manner does not contain cells, problems in transplanting cells can be avoided, and safety is high. In addition, in the production of this tissue improver, it is not necessary to handle living cells, and the culture supernatant that is easy to store is used as a raw material, so the treatment cost is effectively reduced compared to transplanting cells. it can.

  In a biological tissue into which a tissue improving material has been injected, existing cells contained in the living tissue can be activated by growth factors contained in the tissue improving material. As a result, the tissue improvement effect can be obtained not only in the local region where the tissue improving material is injected but also in the surrounding area. That is, by using such a tissue improving material as a skin tissue improving material, the skin tissue into which the tissue improving material has been injected can be improved over a relatively wide range.

  Specifically, for example, by injecting a tissue-improving material into a depressed part such as a wrinkle in a skin tissue of a human patient or a defective part due to a wound or disease, proliferation of cells such as fibroblasts in the injected part and its surroundings And the ability of the cells to produce growth factors and extracellular matrix can be effectively enhanced. As a result, it is possible to regenerate skin tissue by forming a new tissue in a depressed portion or a defective portion.

  Further, for example, by injecting a tissue improving material into a myocardial tissue whose function has been reduced due to local necrosis or the like of the myocardial cell, proliferation and function of the myocardial cell contained in the myocardial tissue can be promoted. As a result, a new tissue can be formed in the necrotic portion and the myocardial tissue can be regenerated. In addition to these, it is also possible to promote the improvement and regeneration of various tissues to which the tissue improving material is injected as described above, such as cerebral blood vessels, bone marrow, bone tissue, and cartilage tissue.

  Such regenerative medicine technology uses cells derived from the human patient's own tissue and injects the growth factor secreted by the cell into the human patient's tissue. It is a cocktail therapy. Therefore, it is possible to effectively improve the tissue of a human patient while reliably avoiding problems such as immune rejection that occurs in allogeneic transplantation and tumor formation that occurs in ES cells and iPS cells.

  In addition, a mixed tissue improving material prepared by mixing a tissue improving material containing a growth factor prepared from a culture supernatant and a tissue improving material containing cells may be produced, and the mixed tissue improving material may be self-transplanted. it can. In this case, a high tissue improvement effect is obtained by the synergistic effect of the growth factor and the living cells.

  11 Step of staining mucosal tissue, 12 Step of identifying deeply stained part, 13 Step of collecting mucosal tissue piece, 14 Step of culturing fibroblast, 15 Step of producing tissue improving material, 16 Transplanting tissue improving material 20 oral mucosal tissue, 21, 22 darkly stained part, 23 lightly dyed part, 24 gingival tissue, L1 upper lip, L2 lower lip, N tongue, T tooth.

Claims (9)

Staining the mucosal tissue with an iodine solution;
Identifying a stained portion of the mucosal tissue that is stained darker than other portions;
Collecting a piece of mucosal tissue from the determined portion of the mucosal tissue;
Culturing fibroblasts derived from the collected pieces of mucosal tissue;
The method characterized by including. A method comprising culturing fibroblasts derived from a piece of mucosal tissue collected from a portion stained darker than other portions of mucosal tissue stained with an iodine solution. The method according to claim 1, further comprising a step of producing a tissue improving material containing the cultured fibroblasts. The method according to claim 3, further comprising a step of transplanting the tissue improving material into a living tissue. The method according to any one of claims 1 to 4, wherein the mucosal tissue is oral mucosal tissue. A fibroblast characterized by being derived from a piece of mucosal tissue collected from a portion of mucosal tissue stained with an iodine solution that is stained darker than other portions. The fibroblast according to claim 6, wherein the mucosal tissue is oral mucosal tissue. A tissue ameliorating material comprising fibroblasts derived from a mucosal tissue piece collected from a portion stained deeper than other portions of a mucosal tissue stained with an iodine solution. The tissue improving material according to claim 8, wherein the mucosal tissue is an oral mucosal tissue.